United States Drug Patent 6,488,027: Claim Scope, Patent Expiration, Inhaler Coverage, and Patent Landscape

U.S. Patent No. 6,488,027 covers an inhaler device with a steel capsule-piercing component protected by a multilayer coating. The broad inventive concept combines an alloy coating with an alloy-polymer composite coating containing inert polymer particles. The preferred embodiment uses nickel-phosphorus and polytetrafluoroethylene, or PTFE.

The patent is directed to device construction, not an active pharmaceutical ingredient, drug formulation, therapeutic method, or biologic. Its U.S. patent term expired in 2020 under the ordinary 20-year term framework. It therefore does not create a current U.S. blocking right, although its claims remain relevant for historical freedom-to-operate analysis, validity reviews, and prior-art mapping.

What does U.S. Patent 6,488,027 cover?

The patent covers an inhaler containing a steel capsule-piercing mechanism with two coating components:

An alloy layer containing a specified metal; and
An alloy matrix layer containing inert polymer particles dispersed in a compatible alloy.

The piercing component may be a needle, pin, blade, or comparable structure that penetrates a capsule used in a dry-powder inhaler. The claim language does not require a particular inhaler brand, active ingredient, capsule material, dose, disease indication, airflow design, or powder formulation.

The critical limitation is the coating architecture. A steel piercing element alone is not enough. The claimed device requires the contact portion of that element to have both an alloy layer and an alloy matrix layer containing polymer particles.

Core patent information

Item	Details
U.S. patent	6,488,027
Title	Inhaler device
Technology	Coated steel capsule-piercing component
Dosage-form context	Dry-powder inhalers using capsules
Independent claim	Claim 1
Narrowest commercially relevant embodiment	Nickel-phosphorus alloy with PTFE-containing nickel-phosphorus matrix
Patent type	Device patent
Drug substance claims	None
Method-of-use claims	None
Formulation claims	None
Orange Book relevance	No direct listing basis as a standalone device patent
U.S. term status	Expired in 2020 under the ordinary patent-term calculation

The patent’s disclosure is directed toward improving the performance of the capsule-piercing mechanism. The coating may reduce corrosion, friction, capsule-material adhesion, wear, and contamination of the inhaled powder. Those functional objectives are relevant to inhaler reliability but are not themselves independent claim limitations unless incorporated through the structural coating requirements.

How broad is claim 1 of U.S. Patent 6,488,027?

Claim 1 is the principal scope-defining claim. It requires five material elements:

Claim element	Scope
Inhaler device	A device, not merely a coating or piercing pin sold separately
Steel capsule-piercing means	A steel structure that pierces a capsule
Contacting portion	At least part of the piercing structure that contacts and penetrates the capsule
Alloy layer	A layer containing chromium, a Group VIII metal, or a noble metal
Alloy matrix layer	A layer containing inert polymer particles and an alloy with a qualifying metal

Claim 1 is broad in device context but narrow in coating configuration. It does not require nickel, phosphorus, PTFE, or any specific coating thickness. Those features appear in dependent claims.

The claim also appears to require two coating layers rather than a single undifferentiated coating. A product with only a nickel coating, only a PTFE coating, or only a polymer-filled metal coating would not literally satisfy all of claim 1 unless the coating structure includes both required layers.

What structures may fall within claim 1?

Potentially covered structures include:

A steel capsule-piercing needle with an underlying nickel-containing alloy layer and an outer nickel-polymer composite layer.
A steel piercing pin coated with a chromium alloy and a polymer-filled alloy matrix.
A capsule-piercing blade with a noble-metal alloy layer and an inert-polymer-containing alloy matrix.
A multilayer electroless coating in which PTFE particles are embedded in a nickel alloy matrix.

The claim does not expressly require that the entire piercing mechanism be coated. Coverage attaches if at least the portion that contacts and pierces the capsule has the specified coating.

What structures fall outside the literal scope?

Potential non-infringing configurations may include:

A polymer-only coating with no qualifying alloy layer.
A single-layer nickel-PTFE coating without a separate alloy layer.
A non-steel piercing mechanism.
A steel piercing mechanism coated only on surfaces that do not contact or pierce the capsule.
A piercing system that opens a blister or foil package rather than a capsule.
A capsule inhaler using an uncoated steel pin.
A coating containing polymer particles but no qualifying chromium, Group VIII, or noble-metal alloy.

These conclusions concern literal claim elements. Equivalents, prosecution history, and claim-construction rulings could affect the historical infringement analysis.

How do claims 2 through 11 narrow the patent scope?

The dependent claims progressively narrow the metal, polymer, composition, and thickness limitations.

Claim	Added limitation	Commercial significance
2	Iron, cobalt, nickel, ruthenium, rhodium, palladium, or combinations	Focuses the generic metal category on a defined group
3	Nickel	Covers the principal practical alloy family
4	Phosphorus in the matrix alloy	Targets nickel-phosphorus or related electroless alloys
5	Nickel and phosphorus	Defines the preferred alloy chemistry
6	90-93 wt% nickel and 7-10 wt% phosphorus	Creates a narrow composition range
7	Fluorocarbon polymer	Narrows the inert polymer class
8	PTFE	Covers the best-defined polymer embodiment
9	Nickel-phosphorus alloy layer plus nickel-phosphorus/PTFE matrix layer	Defines the most commercially specific coating combination
10	Alloy layer 5-15 microns; matrix layer 3-10 microns	Adds dimensional limitations
11	20-30 vol% PTFE in matrix layer	Adds a polymer-loading limitation

Claim 9 is the strongest technical indicator of the intended commercial embodiment. It requires nickel-phosphorus in both the alloy layer and the alloy matrix layer, with PTFE particles in the matrix.

Claim 10 does not depend on claim 9. A product may therefore satisfy the thickness limitations without using nickel-phosphorus or PTFE, provided it satisfies claim 1.

Claim 11 also depends directly on claim 1. It requires the PTFE loading range but does not independently require nickel or phosphorus unless those features are already present through the alloy limitations of claim 1.

What is the narrowest commercially relevant claim?

Claim 9 is the most commercially informative claim, while claims 10 and 11 provide additional process and composition restrictions.

A product satisfying claim 9 would generally have:

A steel capsule-piercing mechanism;
A nickel-phosphorus alloy layer;
A second nickel-phosphorus alloy matrix layer;
PTFE particles dispersed in the matrix layer; and
The coating located on the capsule-contacting and capsule-piercing portion.

A product that also satisfies claims 10 and 11 would have:

A 5-15 micron alloy layer;
A 3-10 micron matrix layer; and
20-30% PTFE by volume in the matrix.

Those features are typically ascertainable through supplier specifications, coating certificates, metallographic cross-sections, energy-dispersive spectroscopy, and polymer-loading analysis.

When did U.S. Patent 6,488,027 lose exclusivity?

The patent lost U.S. patent exclusivity in 2020 under the standard patent-term calculation. The relevant term is generally 20 years from the earliest effective U.S. nonprovisional or international filing date, subject to patent-term adjustment and any applicable extension. No drug patent term extension is expected for this device-only patent because the claims do not cover an approved drug product or a method of using a drug.

Milestone	Approximate timing
Earliest priority and filing period	1999-2000
U.S. patent grant	2002
Standard 20-year term endpoint	2020
Current U.S. enforceability	Expired
Current generic-device blocking effect	None from this patent alone

Patent expiration does not remove the patent from the prior-art record. It eliminates enforceable exclusion rights but leaves the patent available as technical and legal evidence in later proceedings.

Is U.S. Patent 6,488,027 listed in the Orange Book?

The patent is not an ordinary Orange Book patent because its claims are directed to an inhaler device rather than a drug substance, drug product, or method of using an approved drug.

Orange Book patent listings generally concern patents submitted by an NDA holder that claim:

The active ingredient;
The approved drug product or formulation; or
An approved method of use.

A standalone patent on a coated capsule-piercing mechanism does not ordinarily provide a basis for an Orange Book listing. As a result:

It would not normally generate a Paragraph IV certification.
It would not create a 30-month stay based on an ANDA filing.
It would not independently block generic drug approval.
Its expiration would not determine the launch date for a generic inhaled medicine.

The patent could still be commercially relevant if incorporated into a proprietary inhaler used with a drug product protected by separate device, formulation, method-of-use, or drug-substance patents.

Are Paragraph IV challenges relevant to this patent?

Paragraph IV litigation is not directly relevant to this patent as a standalone matter because the patent is not a conventional Orange Book-listed drug patent.

A generic applicant could challenge a separate Orange Book patent covering:

An inhaled active ingredient;
A capsule-based inhalation formulation;
A dose-delivery method;
A drug-device combination;
A specific approved inhaler configuration, if properly listed.

That challenge would not necessarily address U.S. Patent 6,488,027. Conversely, an ANDA applicant could use the patent as prior art in a validity analysis, but it would not be required to certify Paragraph IV against an expired, non-listed device patent.

What patent landscape surrounds coated capsule-piercing inhalers?

The relevant patent landscape has several distinct layers. U.S. Patent 6,488,027 occupies only the coating and piercing-component segment.

Capsule-inhaler architecture patents

These patents typically cover:

A chamber for receiving a capsule;
A capsule-retention structure;
One or more piercing needles;
Actuators that move the needles;
Airflow paths through the pierced capsule;
Dose-dispersion chambers; and
Capsule windows or inspection features.

Such patents can be more commercially significant than the coating patent because they may cover the overall inhaler platform rather than a particular surface treatment.

Formulation and capsule patents

Separate rights may cover:

Lactose-based dry-powder formulations;
Carrier particle size and morphology;
Micronized active pharmaceutical ingredients;
Capsule shell composition;
Low-moisture capsules;
Capsule rupture behavior; and
Dose uniformity after piercing.

U.S. Patent 6,488,027 does not claim any of these features.

Drug-device combination patents

Combination patents may claim the relationship between:

A particular inhaler;
A capsule containing a specified powder;
A dose-loading system; and
A particular therapeutic use.

These claims may create a commercial barrier even when the mechanical coating patent has expired.

Manufacturing and coating patents

The coating field may include separate patents on:

Electroless nickel-phosphorus deposition;
PTFE particle incorporation;
Surface pretreatment of steel;
Coating adhesion;
Thickness control;
Heat treatment;
Corrosion resistance;
Wear resistance; and
Cleaning or passivation of piercing components.

Patent 6,488,027 claims the coated inhaler combination. It does not, based on the supplied claims, claim the coating process in isolation or the coating composition as a standalone article.

How strong was the patent estate?

The patent estate appears narrow in claim count but technically focused.

Strengths

Claim 1 covers a device-level combination rather than a particular commercial brand.
The claim reaches the portion of the piercer that contacts and penetrates the capsule.
The coating architecture is defined by two functional layers.
The claims include broad metal categories before narrowing to nickel, phosphorus, and PTFE.
The patent does not require a specific drug, making the device concept applicable across multiple capsule-based products.

Limitations

The claims require a steel capsule-piercing component.
The coating must include both the alloy layer and alloy matrix layer.
The polymer must be present as particles in the matrix layer.
Dependent claims become narrow when nickel-phosphorus chemistry, thickness, and PTFE loading are required.
The patent does not cover non-capsule inhalers, blister-based inhalers, or devices without a piercing mechanism.
The patent is expired in the United States.
No current Orange Book exclusivity arises from the claims.

The strongest historical enforcement position would have involved a capsule inhaler using a steel needle with a nickel-phosphorus/PTFE multilayer coating. The weakest position would have involved a coating with materially different layer architecture or a non-steel piercing mechanism.

What generic launch risks existed?

During the patent’s active term, a competing capsule inhaler could have faced three principal risks:

Literal infringement by using the claimed multilayer coating.
Infringement under the doctrine of equivalents for a technically interchangeable coating structure.
Commercial access restrictions created by related patents covering the inhaler architecture or drug product.

After expiration, the specific patent no longer presents a U.S. launch barrier. Current launch risk is more likely to arise from:

Active patents on the inhaled drug;
Orange Book-listed formulation patents;
Method-of-use patents;
Device patents with later expiration dates;
Regulatory exclusivity;
Proprietary capsule or dose-metering technology; and
Manufacturing know-how not disclosed in the expired patent.

What biosimilar risk applies?

No biosimilar risk applies directly. Biosimilar litigation concerns biologic products and generally proceeds under the Biologics Price Competition and Innovation Act. The claimed technology is a mechanical inhaler component and does not cover a biologic active ingredient or biologic formulation.

The relevant competitive pathway would be generic or hybrid drug-device development, not biosimilar substitution.

Which companies could be affected by this patent landscape?

The patent could historically have affected companies developing capsule-based dry-powder inhalers, including originator pharmaceutical companies, contract inhaler manufacturers, and device suppliers. Commercial exposure would depend on whether the company:

Owned the inhaler platform;
Purchased coated piercing assemblies;
Licensed capsule-inhaler technology;
Supplied the inhaler to multiple drug manufacturers; or
Used the mechanism in a product with substantial capsule-based sales.

The patent itself does not identify revenue exposure because it claims a device feature rather than a named drug. Revenue analysis therefore depends on mapping the claimed coating architecture to specific inhaler products and supplier drawings.

What geographic coverage did the patent provide?

The U.S. patent provided rights only in the United States. Foreign counterparts, if any, would require separate analysis by jurisdiction. Patent expiration, prosecution history, claim amendments, opposition proceedings, and maintenance status could differ across:

Europe;
The United Kingdom;
Canada;
Japan;
Australia;
China; and
Other national-stage jurisdictions.

A U.S. expiration does not establish that corresponding foreign patents expired on the same date. Conversely, a foreign patent family member would not create a current U.S. infringement risk.

Key Takeaways

U.S. Patent 6,488,027 claims a coated steel capsule-piercing mechanism for a dry-powder inhaler.
Claim 1 requires both an alloy layer and an alloy matrix layer containing inert polymer particles.
The preferred embodiment uses nickel-phosphorus and PTFE.
Claims 9 through 11 define the most commercially specific coating configurations.
The patent does not claim an active ingredient, formulation, therapeutic method, biologic, or drug product.
It is not a conventional Orange Book patent and does not independently create Paragraph IV exposure.
The U.S. patent term expired in 2020 under the ordinary term framework.
Current freedom-to-operate analysis should focus on later-expiring inhaler, formulation, drug-substance, method-of-use, and manufacturing patents.
The historical infringement risk was highest for capsule inhalers using steel piercing pins with nickel-phosphorus/PTFE multilayer coatings.
Biosimilar risk is not relevant to the claimed technology.

FAQs About U.S. Patent 6,488,027

Does the patent cover a PTFE-coated inhaler needle?

Only if the device also has the claimed alloy layer and alloy matrix layer. PTFE alone is insufficient. The matrix must contain polymer particles dispersed in a qualifying alloy.

Does a nickel coating alone infringe claim 1?

Not necessarily. Claim 1 requires a multilayer configuration, including an alloy layer and a separate alloy matrix layer containing inert polymer particles. A single nickel coating without that structure would not literally satisfy claim 1.

Does patent expiration permit unrestricted use of the claimed coating?

In the United States, expiration removes the patent’s exclusionary right. Other patents, trade secrets, regulatory requirements, contractual restrictions, or foreign patent rights may still affect commercialization.

Can an inhaler company challenge this patent through Paragraph IV?

Paragraph IV is generally unavailable as the relevant mechanism for this expired, device-only patent because it is not an ordinary Orange Book-listed drug patent. A company could challenge validity or infringement in another legal context, but not through a standard Paragraph IV certification directed solely to this patent.

Does the patent cover Breezhaler, HandiHaler, or Aerolizer products?

The claim text does not name those products. Coverage depends on whether a particular product uses a steel capsule-piercing component with the required multilayer alloy and polymer-particle coating. Product-specific conclusions require claim-chart evidence concerning the actual coating structure.

References

U.S. Patent No. 6,488,027. (2002). Inhaler device. United States Patent and Trademark Office. https://patents.google.com/patent/US6488027
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
United States Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
United States Patent and Trademark Office. (2024). Manual of patent examining procedure: Patent term. https://www.uspto.gov/web/offices/pac/mpep/
U.S. Food and Drug Administration. (2024). Abbreviated new drug application and patent certification procedures. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-instructions

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9805102	Mar 10, 1998

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	283083	⤷ Start Trial
Australia	3032399	⤷ Start Trial
Australia	750844	⤷ Start Trial
Brazil	9908587	⤷ Start Trial
Brazil	9908626	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,488,027

Summary for Patent: 6,488,027